Who
Nir Nimrodi
Director
Company insider
Files Form 4 as: Director, Evogene; Chief Business Officer, Precigen.
In numbers
- Trades disclosed
- 11
- Buys
- 2
- Sells
- 1
- Bought
- $168K
- Sold
- $29K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 17 Mar 2014
- Last trade
- 4 Sep 2026
- Last filed
- 30 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 30 Sep 2026 | EVGN Evogeneoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Sep 2026filed 30 Sep 2026 | EVGN Evogeneoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jan 2019filed 8 Jan 2019 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,758 at $0.00 | filing |
| 4 Jan 2019filed 8 Jan 2019 | PGEN PrecigenBiotechnology | SEC FORM 4 Code A | —13,774 | filing |
| 3 Jan 2019filed 4 Jan 2019 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $29K4,058 at $7.07 | filing |
| 2 Jan 2019filed 4 Jan 2019 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,766 at $0.00 | filing |
| 2 Jan 2019filed 4 Jan 2019 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —9,766 | filing |
| 2 Jan 2018filed 8 Jan 2018 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,063 at $0.00 | filing |
| 11 Aug 2017filed 14 Aug 2017 | PGEN PrecigenBiotechnology | SEC FORM 4 Bought | $63K3,369 at $18.75 | filing |
| 29 Aug 2016filed 31 Aug 2016 | PGEN PrecigenBiotechnology | SEC FORM 4 Bought | $104K4,000 at $26.12 | filing |
| 17 Mar 2014filed 19 Mar 2014 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.